OSCR

Enhanced therapeutic potential of paeoniflorin and vitamin B12 in intracerebropeduncle ethidium bromide-induced multiple sclerosis-like pathology.

Overview

Authors: MD Nasiruddin Khan1, Sidharth Mehan1, Divya Choudhary1, Ravi Rana1, Ghanshyam Das Gupta2, Acharan S. Narula3
  1. Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to IK Gujral Punjab Technical University), Jalandhar, Punjab, India
  2. Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to IK Gujral Punjab Technical University), Jalandhar, Punjab, India
  3. Narula Research, LLC, Chapel Hill, NC, United States
Institutions: Punjab Technical University (India)
Journal: Frontiers in pharmacology, volume 17, article 1792674
Dates: received 21 January 2026; accepted 5 March 2026; published online 10 April 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3389/fphar.2026.1792674 · PMID 42038309 · PMCID PMC13106211 · OpenAlex W7153289485
Open access: gold, a free copy (OpenAlex)
Categories: multiple sclerosis (population), clinical / translational (subfield)
Methods: Statistics
Keywords: Akt, demyelination, ERK1/2, ethidium bromide (EBRO), gdnf, Gfra1, GSK3-beta, multiple sclerosis (MS)
Topic: Multiple Sclerosis Research Studies (Clinical Neurology, Medicine), according to OpenAlex
Citations: cited by 1 paper (Europe PMC); 159 references in the paper

Abstract

The study investigates the neuroprotective potential of paeoniflorin (PNN) in mitigating the multifaceted pathology of multiple sclerosis (MS) in an ethidium bromide-induced (EBRO) rat model. A comprehensive approach utilizing in silico, in-vitro, and in-vivo methodologies reveals that PNN targets key molecular pathways implicated in MS, including the GDNF/GFRA1/RET/AKT/ERK1/2/GSK3-Beta signaling cascade. PNN (50 mg/kg, 100 mg/kg, p.o.) administration, both as monotherapy and in combination with VB-12 (30 mg/kg, p.o.), demonstrated significant efficacy in reducing EBRO-induced neurodegeneration, demyelination, synaptic dysfunction, and neuroinflammation. Behavioral assessments such as the rotarod, beam crossing, and Morris water maze tests highlighted PNN capacity to restore motor coordination, spatial memory, and cognitive function. Combination therapy with VB12 (30) further enhanced these outcomes, demonstrating synergistic therapeutic benefits. Histological and molecular analyses revealed that PNN100 alleviates demyelination, reduces inflammatory cytokines TNF-α, IL-1β, and restores anti-inflammatory markers (IL-10) in brain homogenates, CSF, and blood plasma. Moreover, PNN normalized neurotransmitter imbalances, including elevated glutamate and reduced GABA, dopamine, serotonin, and acetylcholine levels, highlighting its role in restoring excitatory-inhibitory balance. ELISA studies confirmed PNN ability to modulate apoptotic markers Bax, Bcl-2, and Caspase-3 and upregulate neurotrophic factors GDNF, and GFRA1 while downregulating hyperactivated pathways like AKT, ERK1/2, and GSK3-Beta. Additionally, hematological parameters disrupted by EBRO were significantly restored by PNN, indicating its systemic anti-inflammatory and hematoprotective effects. This research provides the first evidence of PNN’s role in modulating the GDNF/GFRA1/RET/AKT/ERK1/2/GSK3β pathway in MS. Its synergistic action with VB12 underscores its potential as a combinatorial therapeutic strategy. The findings pave the way for innovative treatment approaches to improve outcomes for MS patients by addressing neurodegeneration, inflammation, and systemic immune dysregulation.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 6 authors, 8 keywords, 156 references.

Cite

This paper

Khan, M. N., Mehan, S., Choudhary, D., Rana, R., Das Gupta, G., & Narula, A. S. (2026). Enhanced therapeutic potential of paeoniflorin and vitamin B12 in intracerebropeduncle ethidium bromide-induced multiple sclerosis-like pathology. Frontiers in pharmacology, 17, 1792674. https://doi.org/10.3389/fphar.2026.1792674

BibTeX

@article{khan2026enhanced,
author = {Khan, MD Nasiruddin and Mehan, Sidharth and Choudhary, Divya and Rana, Ravi and Das Gupta, Ghanshyam and Narula, Acharan S.},
title = {{Enhanced therapeutic potential of paeoniflorin and vitamin B12 in intracerebropeduncle ethidium bromide-induced multiple sclerosis-like pathology}},
journal = {Frontiers in pharmacology},
year = {2026},
month = apr,
volume = {17},
pages = {1792674},
publisher = {Frontiers Media SA},
issn = {1663-9812},
doi = {10.3389/fphar.2026.1792674},
url = {https://doi.org/10.3389/fphar.2026.1792674},
pmid = {42038309},
pmcid = {PMC13106211}
}

RIS

TY - JOUR
AU - Khan, MD Nasiruddin
AU - Mehan, Sidharth
AU - Choudhary, Divya
AU - Rana, Ravi
AU - Das Gupta, Ghanshyam
AU - Narula, Acharan S.
TI - Enhanced therapeutic potential of paeoniflorin and vitamin B12 in intracerebropeduncle ethidium bromide-induced multiple sclerosis-like pathology
T2 - Frontiers in pharmacology
J2 - Front Pharmacol
PY - 2026
DA - 2026/04/10
VL - 17
SP - 1792674
SN - 1663-9812
PB - Frontiers Media SA
DO - 10.3389/fphar.2026.1792674
UR - https://doi.org/10.3389/fphar.2026.1792674
LA - en
ER -

CSL-JSON

{
"id": "10.3389/fphar.2026.1792674",
"type": "article-journal",
"title": "Enhanced therapeutic potential of paeoniflorin and vitamin B12 in intracerebropeduncle ethidium bromide-induced multiple sclerosis-like pathology",
"container-title": "Frontiers in pharmacology",
"author": [
{
"family": "Khan",
"given": "MD Nasiruddin"
},
{
"family": "Mehan",
"given": "Sidharth"
},
{
"family": "Choudhary",
"given": "Divya"
},
{
"family": "Rana",
"given": "Ravi"
},
{
"family": "Das Gupta",
"given": "Ghanshyam"
},
{
"family": "Narula",
"given": "Acharan S."
}
],
"container-title-short": "Front Pharmacol",
"volume": "17",
"page": "1792674",
"DOI": "10.3389/fphar.2026.1792674",
"PMID": "42038309",
"PMCID": "PMC13106211",
"ISSN": "1663-9812",
"publisher": "Frontiers Media SA",
"URL": "https://doi.org/10.3389/fphar.2026.1792674",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
10
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1016/j.heliyon.2024.e24050
Icariin prevents methylmercury-induced experimental neurotoxicity: Evidence from cerebrospinal fluid, blood plasma, brain samples, and in-silico investigations.
Journal: Heliyon
In common: 13 references, author Sidharth Mehan
[2] doi:10.1038/s41593-026-02201-7 [code]
Autoimmune neuroinflammation leads to neuronal death via MIF nuclease-mediated parthanatos.
Journal: Nature neuroscience
In common: multiple sclerosis, 3 references
[3] doi:10.1186/s13024-022-00538-8
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination.
Journal: Molecular neurodegeneration
In common: multiple sclerosis, 2 references
[4] doi:10.1093/cei/uxae032
Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.
Journal: Clinical and experimental immunology
In common: multiple sclerosis, 2 references
[5] doi:10.1016/j.nicl.2021.102854 [code]
ALL-Net: Anatomical information lesion-wise loss function integrated into neural network for multiple sclerosis lesion segmentation.
Journal: NeuroImage. Clinical
In common: multiple sclerosis, 2 references
[6] doi:10.1038/s41598-025-01465-6 [code]
White matter volume and microstructural integrity are associated with fatigue in relapsing multiple sclerosis.
Journal: Scientific reports
In common: multiple sclerosis, clinical / translational, 1 reference
[7] doi:10.1128/msystems.00416-26 [code]
Integrative multicohort analysis reveals consistent sex differences in gut microbiota of multiple sclerosis patients.
Journal: mSystems
In common: multiple sclerosis, clinical / translational, 1 reference
[8] doi:10.1111/cns.13793
Role of lipoic acid in multiple sclerosis.
Journal: CNS neuroscience & therapeutics
In common: multiple sclerosis, clinical / translational, 1 reference
[9] doi:10.1093/braincomms/fcae295 [code]
Patterns of cerebral damage in multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders-major differences revealed by non-conventional imaging.
Journal: Brain communications
In common: multiple sclerosis, clinical / translational, 1 reference
[10] doi:10.1002/hbm.26464
Lifespan neurodegeneration of the human brain in multiple sclerosis.
Journal: Human brain mapping
In common: multiple sclerosis, clinical / translational, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.